The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).
Nicholas J. Vogelzang
Consultant or Advisory Role - Bayer; Bayer
Research Funding - Bayer
Chris Parker
Consultant or Advisory Role - Algeta (U); Bayer
Sten Nilsson
Consultant or Advisory Role - Algeta
Jose Garcia-Vargas
Employment or Leadership Position - Bayer
Robert Edward Coleman
Honoraria - Amgen; Bayer
Expert Testimony - Novartis
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer